Ngomhla wama-21 ku-Epreli, ngo-2026, iZiko loVavanyo lwaMayeza (i-CDE) le-National Medical Products Administration libhengeze ukuba i-HS-20093 yokujova (risvutatug rezetecan) ikhethwe njengoMviwa we-Breakthrough Therapy wokunyanga izigulana ezinomhlaza we-prostate onganyangekiyo ophucukileyo ezifumene unyango olutsha lwe-hormone kunye ne-taxane-based chemotherapy. Ezi ndaba zizisa ithemba elitsha kwizigulana ezinomhlaza we-prostate kwihlabathi liphela.
I-HS-20093 (HS-20093 / GSK5764227) yi-B7-H3-targeting antibody-drug conjugate (ADC) eyenziwe ngokuzimeleyo yiHansoh. Kwi-2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026), iziphumo ezivela kwi-open-label, multicenter Phase II trial ebizwa ngokuba yi-ARTEMIS-003 (NCT06001255) zavezwa ngokusesikweni. Olu phononongo luvavanye ukusebenza kakuhle kunye nokhuseleko lwe-HS-20093 kwizigulane ezine-metastatic castration-resistant prostate cancer (mCRPC) eziye zaqhubeka emva konyango olunye lwangaphambili.
Iziphumo bezikhuthaza:
- **Kwizigulana ezazinyangwe nge-taxanes ngaphambili:** izinga lokuphendula elingqinisisiweyo (cORR) yayingama-38.9%, kwaye izinga lokuphendula le-prostate-specific antigen (PSA) (≥50% ukuhla) yayiyi-40.7%.
- **Kwizigulane ezingazange zinyangwe nge-taxanes ngaphambili:** izinga lokuphendula elingqinisisiweyo (uORR) lalingama-41.7%, kwaye izinga lokuphendula le-PSA50 lalingama-23.8%.
Ezi datha zibonisa ukuba i-HS-20093 ibonisa umsebenzi obalulekileyo nohlala ixesha elide wokulwa nomhlaza nokuba ikhemotherapi yayikhe yasetyenziswa ngaphambili. Kwizigulane ezinezifo eziqhubekekayo eziye zakwazi ukumelana nomhlaza okanye eziphinde zabuyela umva emva konyango oluqhelekileyo lwangoku (unyango olutsha lwehomoni + ikhemotherapi), oku ngokungathandabuzekiyo kubonisa ukhetho olutsha noluxabisekileyo ngokwezonyango.
**Izigulane zamazwe ngamazwe zingalufikelela njani olu nyango luphambili?**
Ukuba wena okanye ilungu losapho nilwa nomhlaza weprostate onganyangekiyo kwi-castration kwaye awaneliswanga okanye aninyamezelani neendlela zonyango ezikhoyo, ngoku ningathetha neSebe le-International Department of Beijing South Region Oncology Hospital ukuze nivavanye ukufaneleka konyango lwe-HS-20093. Njengeziko elikhethekileyo elikwaziyo ukubonelela ngeenkonzo zonyango zamazwe ngamazwe, iSebe le-International Department lesibhedlele lizimisele ukubonelela ngononophelo olupheleleyo lwe-oncology kwizigulana zehlabathi, kubandakanya ukufikelela kwiimvavanyo zeklinikhi ezintsha kunye nonyango oluphambili.
**Nxibelelana nathi ngoku:**
- **Inombolo yefowuni:** 400-880-3716
- **I-ID ye-WeChat:** 17801183037
- **I-imeyile:**
① 100085_010@163.com
② myimmnet@163.com
**Amanqaku abalulekileyo:**
- Ngaphambi kokuba batyelele, izigulane zamazwe ngamazwe kufuneka zilungiselele iinguqulelo zesiNgesi/zesiTshayina zeerekhodi zonyango zangaphambili (kuquka iingxelo zezifo, ukuvavanywa kwemifanekiso, kunye neerekhodi zekhemotherapy zangaphambili kunye nonyango lwehomoni) ukuze kube lula ukuvavanya ugqirha ngokukhawuleza.
- ISebe lethu leHlabathi lingakunceda ngeeleta zesimemo se-visa yezonyango, amadinga, kunye neenkonzo zokuguqulela. Ukuba unemibuzo ethile, nceda unxibelelane nathi ngezi ndlela zingasentla.
Ixesha leposi: Epreli-28-2026